On this page you will find useful information regarding which patients should be initiated on OPSUMIT®, guidance on prescribing and administering OPSUMIT®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension proceedings, and recommendations for screening and diagnosing patients with scleroderma or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).
Access the OPSUMIT® SmPC and patient information leaflet.
Learn how PAH can impact patients with scleroderma.
Learn about the investigation and referral pathways for patients with scleroderma and suspected PAH.
Learn how PAH can impact patients with CHD.
Learn about the investigation and referral pathways for patients with CHD and suspected PAH.
Discover how OPSUMIT® can provide a range of benefits for patients with PAH.
OPSUMIT® has a well-characterised and generally manageable safety profile.
OPSUMIT® is recommended in first line as monotherapy and in combination therapy by the 2015 ESC/ERS guidelines.
CHD, congenital heart disease; ERS, European Respiratory Society; ESC, European Society of Cardiology; PAH, pulmonary arterial hypertension; PHA, Pulmonary Hypertension Association; WSPH, World Symposium on Pulmonary Hypertension
CP-220224 ∣ June 2021
OPSUMIT® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING